TheBrief.Health
New evidence supports sequential pembrolizumab after radiotherapy for high-risk Merkel cell carcinoma, reducing disease recurrence, preventing distant metastases, and reshaping multidisciplinary postoperative treatment strategies.
526 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de TheBrief.Health!